nach oben

Erschienen in:

27.06.2018 | Original Communication

Assessment of Duodopa^® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers

verfasst von: Rosella Ciurleo, Francesco Corallo, Lilla Bonanno, Viviana Lo Buono, Giuseppe Di Lorenzo, Roberta Versaci, Cettina Allone, Rosanna Palmeri, Placido Bramanti, Silvia Marino

Erschienen in: Journal of Neurology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

The gold standard of treatment in Parkinson’s disease (PD) is levodopa/carbidopa whose long-term use induces motor and non-motor fluctuations and dyskinesias. Continuous infusion of intrajejunal levodopa/carbidopa intestinal gel (Duodopa^®) reduces motor and non-motor symptoms and dyskinesias, and improves the quality of life of patients. The aim of this open observational prospective study was to evaluate the impact of Duodopa^® on conditions of PD patients and caregivers, and their quality of life. We enrolled 12 patients with advanced PD and their caregivers. The PD patients were assessed at baseline, 3 and 6 months after Duodopa^® treatment initiation using Unified Parkinson’s Disease Rating Scale-Part III and IV (UPDRS-III and IV), Unified Dyskinesia Rating Scale (UdysRS), Beck Depression Inventory (BDI-II), Hamilton Anxiety Rating Scale (HAM-A) and Parkinson’s Disease Quality of Life Questionnaire (PDQ-39). The caregivers were assessed, at the same time as the patients, using BDI-II, HAM-A, Caregiver Burden Inventory (CBI) and SF-36 Health Status Questionnaire. Six months after Duodopa^® therapy, the scores of UPDRS-III and IV, UdysRS, BDI-II, HAM-A and PDQ-39 were significantly decreased (p < 0.01). After Duodopa^® therapy, in caregiver group the scores of BDI-II, HAM-A and CBI were significantly decreased and the scores of SF-36 Health Status Questionnaire were significantly increased (p < 0.01). A reduction of anxiety after therapy correlated with mental status domains of SF-36 Health Status Questionnaire (r = 0.56). Overall, Duodopa^® is effective even in the short time to improve the clinical conditions of PD patients and caregivers and their quality of life.

Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N et al (2000) Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci 23:S8–S19CrossRefPubMed

Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S2–S41. https://doi.org/10.1002/mds.23829 CrossRefPubMed

Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias s and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458. https://doi.org/10.1002/mds.1090 CrossRefPubMed

Gunal DI, Nurichalichi K, Tuncer N, Bekiroglu N, Aktan S (2002) The clinical profile of nonmotor fluctuation in Parkinson’s disease patients. Can J Neurol Sci 29:61–64CrossRefPubMed

Cedarbaum JM (1987) Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet 13:141–178CrossRefPubMed

Nutt JG (2008) Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 23:S580–S584. https://doi.org/10.1002/mds.22037 CrossRefPubMed

Mouradian MM, Juncos JL, Fabrini G, Chase TN (1989) Motor fluctuations in Parkinson’s disease. Ann Neurol 25:633–634CrossRef

Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:337–345

Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parekinson’s disease on the quality of life. Mov Disord 20:224–230. https://doi.org/10.1002/mds.20279 CrossRefPubMed

10.

Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P et al (2013) Nonmotor fluctuations in Parkinson desease: severity and correlation with motor complications. Neurology 80:800–809. https://doi.org/10.1212/WNL.0b013e318285c0ed CrossRefPubMed

11.

Palmeri R, Lo Buono V, Corallo F, Foti M, Di Lorenzo G, Bramanti P et al (2017) Nonmotor symptoms in Parkinson disease: a descriptive review on social cognition ability. J Ger Psych Neurol 30:109–121. https://doi.org/10.1177/0891988716687872 CrossRef

12.

Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J et al (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–441CrossRefPubMed

13.

Martinez-Martin P, Forijaz MJ, Frades-Pyo B, Rusiñol AB, Fernández-García JM, Benito-León J et al (2007) Caregiver burden in Parkinson’s disease. Mov Disord 22:924–931. https://doi.org/10.1002/mds.21355 CrossRefPubMed

14.

Martinez-Martin P, Arroyo S, Rojo-Abuin JM, Rodriguez-Blazquez C, Frades B, de Pedro Cuesta J (2008) Longitudinal Parkinson’s Disease Patient Study (Estudio longitudinal de pacientes con enfermedad de Parkinson-ELEP) Group. Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Mov Disord 23:1673–1680. https://doi.org/10.1002/mds.22106 CrossRefPubMed

15.

Rascol O, Perez-Lloret S, Ferreira JJ (2015) New treatments for levodopa-induced motor complications. Mov Disord 30:1451–1460. https://doi.org/10.1002/mds.26362 CrossRefPubMed

16.

LeWitt PA (2016) New levodopa therapeutic strategies. Parkinsonism Relat Disord 22:S37–S40. https://doi.org/10.1016/j.parkreldis.2015.09.021 CrossRefPubMed

17.

Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B et al (2017) Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson’s disease patients. Mov Disord 32:235–240. https://doi.org/10.1002/mds.26848 CrossRefPubMed

18.

De Fabregues O, Dot J, Abu-Suboh M, Hernández-Vara J, Ferré A, Romero O et al (2017) Long-term safety and effectiveness of levodopa–carbidopa intestinal gel infusion. Brain Behav 7:e00758. https://doi.org/10.1002/brb3.758 CrossRefPubMedPubMedCentral

19.

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z et al (2017) Levodopa–carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018 CrossRefPubMed

20.

Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L et al (2007) Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 22:1145–1149. https://doi.org/10.1002/mds.21500 CrossRefPubMed

21.

Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis 5:244–246. https://doi.org/10.1159/000113714 CrossRefPubMed

22.

Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study Investigators and Coordinators (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa–carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 21:231–235. https://doi.org/10.1016/j.parkreldis.2014.12.012 CrossRefPubMed

23.

Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson’s disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151–166. https://doi.org/10.1097/wnf.0b013e31814b113e CrossRefPubMed

24.

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474. https://doi.org/10.1002/mds.22596 CrossRefPubMed

25.

Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J et al (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126:29–33. https://doi.org/10.1111/j.1600-0404.2012.01689.x CrossRef

26.

Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L et al (2013) Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol 260:105–114. https://doi.org/10.1007/s00415-012-6597-0 CrossRefPubMed

27.

Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D et al (2014) Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol 21:312–318. https://doi.org/10.1111/ene.12309 CrossRefPubMed

28.

Foltynie T, Magee C, James C, Webster GJ, Lees AJ, Limousin P (2013) Impact of duodopa on quality of life in advanced Parkinson’s disease: a UK case series. Parkinsons Dis 2013:362908. https://doi.org/10.1155/2013/362908 PubMedPubMedCentralCrossRef

29.

Bohlega S, Abou Al-Shaar H, Alkhairallah T, Al-Ajlan F, Hasan N, Alkahtani K (2015) Levodopa–carbidopa intestinal gel infusion therapy in advanced Parkinson’s disease: single middle eastern center experience. Eur Neurol 74:227–236. https://doi.org/10.1159/000442151 CrossRefPubMed

30.

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F et al (2015) Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month. Open-label results. Mov Disord 30:500–509. https://doi.org/10.1002/mds.26123 CrossRefPubMed

31.

Bellante F, Dethy S, De Beyl DZ (2016) Depression, anxiety and non-motor symptoms on initiation ogf intrajejunal levodopa/carbodopa therapy. Acta Neurol Belg 116:39–41. https://doi.org/10.1007/s13760-015-0497-x CrossRefPubMed

32.

Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N (2012) Intrajejunal levodopa infusion in advanced Parkinson’s disease: long-term effects on motor and non-motor symptoms and impact on patients’ and caregivers’ quality of life. Eur Rev Med Pharmacol Sci 16:79–89PubMed

33.

Santos-García D, Añón MJ, Fuster-Sanjurjo L, de la Fuente-Fernández R (2012) Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. Eur J Neurol 19:1261–1265. https://doi.org/10.1111/j.1468-1331.2011.03630.x CrossRefPubMed

34.

Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Movement Disorder Society UPDRS Revision Task Force et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340 CrossRefPubMed

35.

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x CrossRefPubMed

36.

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314CrossRefPubMed

37.

Nutt J (1999) A unified dyskinesias s rating scale for L-dopa-induced dyskinesias? Mov Disord 14(Suppl 1):74PubMed

38.

Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. San Antonio, TX, p 78204

39.

Schneider H, Esbitt S, Gonzalez JS (2013) Hamilton anxiety rating scale. Encyclopedia of behavioral medicine. Springer, New York, pp 886–887

40.

Peto V, Jenkinson C, Fitzpatrick R (1998) PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 245:S10–S14CrossRefPubMed

41.

Novak M, Guest C (1989) Application of a multidimensional caregiver burden inventory. Gerontologist 29:798–803CrossRefPubMed

42.

Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B (1994) Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 94:182–188. https://doi.org/10.1053/ai.1994.v94.a54939 CrossRefPubMed

43.

Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PMM (2003) On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res 12(4):349–362CrossRefPubMed

44.

Sullivan GM, Feinn R (2012) Using effect size—or why the P value is not enough. J Grad Med Educ 4(3):279–282CrossRefPubMedPubMedCentral

45.

Lutz SG, Holmes JD, Ready EA, Jenkins ME, Johnson AM (2016) Clinical presentation of anxiety in Parkinson’s Disease: a scoping review. OTJR (Thorofare N J) 36:134–147. https://doi.org/10.1177/1539449216661714 CrossRef

46.

Yamanishi T, Tachibana H, Oguru M, Matsui K, Toda K, Okuda B et al (2013) Anxiety and depression in patients with Parkinson’s disease. Intern Med 52:539–545. https://doi.org/10.2169/internalmedicine.52.8617 CrossRefPubMed

47.

Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol 23:854–860. https://doi.org/10.1111/ene.12950 CrossRefPubMed

48.

Berganzo K, Tijero B, González-Eizaguirre A, Somme J, Lezcano E, Gabilondo I et al (2016) Motor and non-motor symptoms of Parkinson’s disease and their impact on quality of life and on different clinical subgroups. Neurologia 31:585–591. https://doi.org/10.1016/j.nrl.2014.10.010 CrossRefPubMed

49.

Foppa AA, Chemello C, Vargas-Peláez CM, Farias MR (2016) Medication therapy management service for patients with Parkinson’s disease: a before-and-after study. Neurol Ther 5:85–99. https://doi.org/10.1007/s40120-016-0046-4 CrossRefPubMedPubMedCentral

50.

Carter JH, Stewart BJ, Archbold PG, Parkinson’s Study Group et al (1998) Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Mov Disord 13:20–28. https://doi.org/10.1002/mds.870130108 CrossRefPubMed

51.

Ozdilek B, Gunal DI (2012) Motor and non-motor symptoms in Turkish patients with Parkinson’s disease affecting family caregiver burden and quality of life. J Neuropsychiatry Clin Neurosci 24:478–483. https://doi.org/10.1176/appi.neuropsych.11100315 CrossRefPubMed

Titel: Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers
verfasst von: Rosella Ciurleo
Francesco Corallo
Lilla Bonanno
Viviana Lo Buono
Giuseppe Di Lorenzo
Roberta Versaci
Cettina Allone
Rosanna Palmeri
Placido Bramanti
Silvia Marino
Publikationsdatum: 27.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 9/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-8951-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Assessment of Duodopa^® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Primary progressive freezing gait with impressive response to laser light visual cueing: a video case report

Are visual functions diagnostic signs of the minimally conscious state? an integrative review

Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials

Bernardino Ramazzini (1633–1714)

Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias

Corpus callosal involvement is correlated with cognitive impairment in multiple system atrophy

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie